How much revenue did GenKyoTex generate this year?
GenKyoTex has achieved a revenue of -9,186.9 TT this year.
GenKyoTex Revenue 2024
GenKyoTex Revenue
-9,186.9 TT
Ticker
GKTX.PA
ISIN
FR0013399474
WKN
A2PE0M
In 2024, GenKyoTex's sales reached -9,186.9 TT , a -1.67% difference from the -9,343.17 TT sales recorded in the previous year.
The GenKyoTex Revenue history
| YEAR | REVENUE (undefined ) | GROSS MARGIN (%) |
|---|---|---|
| 2024e | - | - |
| 2023e | - | - |
| 2022e | - | - |
| 2021e | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
| 2015 | - | - |
| 2014 | - | - |
| 2013 | - | - |
| 2012 | - | - |
| 2011 | - | - |
GenKyoTex Revenue, EBIT, Net Income FR0013399474 · A2PE0M
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into GenKyoTex, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GenKyoTex from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GenKyoTex’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of GenKyoTex. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into GenKyoTex’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing GenKyoTex’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GenKyoTex’s growth potential.
GenKyoTex Revenue, EBIT and net profit per share
| Date | GenKyoTex Revenue | GenKyoTex EBIT | GenKyoTex Net Income |
|---|---|---|---|
| 2024e | -9,186.9 TT | 0 | 0 |
| 2023e | -9,343.17 TT | 0 | 0 |
| 2022e | 0 | 0 | -3.01 M |
| 2021e | 0 | 0 | -1.91 M |
| 2020 | 0 | -14 M | -14.06 M |
| 2019 | 0 | -7.22 M | -7.2 M |
| 2018 | 0 | -10.86 M | -11.42 M |
| 2017 | 0 | -25.22 M | -25.77 M |
| 2016 | 0 | -5.76 M | -6.7 M |
| 2015 | 0 | -11.42 M | -11.19 M |
| 2014 | 0 | -10.83 M | -10.94 M |
| 2013 | 0 | -6.05 M | -5.96 M |
| 2012 | 0 | -5.38 M | -5.65 M |
| 2011 | 0 | -5.21 M | -5.2 M |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 0 | -5.21 M | -5.2 M |
| 2012 | 0 | -5.38 M | -5.65 M |
| 2013 | 0 | -6.05 M | -5.96 M |
| 2014 | 0 | -10.83 M | -10.94 M |
| 2015 | 0 | -11.42 M | -11.19 M |
| 2016 | 0 | -5.76 M | -6.7 M |
| 2017 | 0 | -25.22 M | -25.77 M |
| 2018 | 0 | -10.86 M | -11.42 M |
| 2019 | 0 | -7.22 M | -7.2 M |
| 2020 | 0 | -14 M | -14.06 M |
| 2021e | 0 | 0 | -1.91 M |
| 2022e | 0 | 0 | -3.01 M |
| 2023e | -9,343.17 TT | 0 | 0 |
| 2024e | -9,186.9 TT | 0 | 0 |
GenKyoTex stock margins FR0013399474 · A2PE0M
The GenKyoTex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GenKyoTex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GenKyoTex.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the GenKyoTex's sales revenue. A higher gross margin percentage indicates that the GenKyoTex retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the GenKyoTex's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the GenKyoTex's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GenKyoTex's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GenKyoTex. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GenKyoTex's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
GenKyoTex Margin History
| GenKyoTex Gross margin | GenKyoTex Profit margin | GenKyoTex EBIT margin | GenKyoTex Profit margin |
|---|---|---|---|
| 2024e | 0 % | 0 % | 0 % |
| 2023e | 0 % | 0 % | 0 % |
| 2022e | 0 % | 0 % | 0 % |
| 2021e | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2011 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021e | 0 % | 0 % | 0 % |
| 2022e | 0 % | 0 % | 0 % |
| 2023e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
GenKyoTex Aktienanalyse
What does GenKyoTex do?
GenKyoTex SA is a Swiss biotechnology company specializing in the development of innovative therapies for the treatment of inflammatory diseases. The company was founded in 2006 by Dr. Elias Papatheodorou and Dr. Takashi Mizuno and is headquartered near Lausanne. The history of GenKyoTex SA began with the discovery of a new enzyme called NOX (NADPH oxidase) 1/4, which plays a crucial role in the onset of inflammation. This was the starting point for the development of inhibitors that reduce NOX activity and thus halt the progression of inflammatory diseases such as fibrosis, arthritis, or kidney failure. GenKyoTex SA's business model is based on the development and marketing of therapeutics based on NOX inhibitor technology. The company works closely with leading experts and research institutions to develop innovative drugs and conduct clinical trials. The different divisions of GenKyoTex SA include expertise in formulation, manufacturing, and stabilization of active ingredients and drugs, as well as the development of clinical trials and optimization of production processes. The company has its own research and development department, allowing it to oversee the entire value chain associated with its products. The company has developed a range of products based on NOX inhibitor technology. One of these is GKT831, a drug used to treat patients with idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive condition in which lung tissue becomes inflamed and scarred, impairing oxygen uptake. GKT831 has shown promising results in a clinical program. Another product from GenKyoTex SA is GKT771, a drug used to treat patients with diabetic nephropathy. Diabetic nephropathy is a complication of diabetes in which kidney function deteriorates. GKT771 has shown positive results in a phase 2 study and is now in phase 3 development. Overall, GenKyoTex SA is an innovative company focused on the development of drugs for the treatment of inflammation. The company has expertise in NOX inhibitor technology and has already brought several promising products to market or in development. Thanks to collaboration with leading experts and research institutions, GenKyoTex SA can accelerate the development of new drugs and improve patients' quality of life. GenKyoTex ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding GenKyoTex's Sales Figures
The sales figures of GenKyoTex originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing GenKyoTex’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize GenKyoTex's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in GenKyoTex’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about GenKyoTex stock
How much was the turnover of the company GenKyoTex compared to the previous year?
The revenue of GenKyoTex has increased by -1.67% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of GenKyoTex?
The revenue of GenKyoTex is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of GenKyoTex measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of GenKyoTex so important for investors?
The revenue of GenKyoTex is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does GenKyoTex pay?
Over the past 12 months, GenKyoTex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GenKyoTex is expected to pay a dividend of 0 .
What is the dividend yield of GenKyoTex?
The current dividend yield of GenKyoTex is .
When does GenKyoTex pay dividends?
GenKyoTex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of GenKyoTex?
GenKyoTex paid dividends every year for the past 0 years.
What is the dividend of GenKyoTex?
For the upcoming 12 months, dividends amounting to 0 are expected. This corresponds to a dividend yield of 0 %.
In which sector is GenKyoTex located?
GenKyoTex is assigned to the 'Health' sector.
Wann musste ich die Aktien von GenKyoTex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of GenKyoTex from 9/14/2024 amounting to 0 , you needed to have the stock in your portfolio before the ex-date on 9/14/2024.
When did GenKyoTex pay the last dividend?
The last dividend was paid out on 9/14/2024.
What was the dividend of GenKyoTex in the year 2023?
In the year 2023, GenKyoTex distributed 0 as dividends.
In which currency does GenKyoTex pay out the dividend?
The dividends of GenKyoTex are distributed in .
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von GenKyoTex
Our stock analysis for GenKyoTex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GenKyoTex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
